Clinical trial NCT04508530: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Official title: A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pediatric Acute-Onset Neuropsychiatric Syndrome
Lead sponsor: Octapharma
Sponsor class: INDUSTRY
First posted: 2020-08-11
Enrollment: 71
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome


Eligibility criteria: Inclusion Criteria:

1. Patients ≥6 to ≤17 years of age.
2. Confirmed diagnosis of moderate to severe PANS with prominent and stable obsessive-compulsive disorder (OCD) symptoms (i.e. Clinical Global Impression (CGI)-Severity-OCD rating of ≥ 4 or higher on 2 ratings without a change of more than 1 unit between measurements) based on the following criteria:

   1. Abrupt dramatic onset of OCD meeting DSM-5 diagnostic criteria for OCD as confirmed by the MINI-KID-7
   2. Concurrent presence of additional neuropsychiatric symptoms, with similarly severe and acute onset, from at least two of the following seven categories, that are not better explained by a known neurologic or medical disorder, such as Sydenham chorea (SC), systemic lupus erythematosus, Tourette disorder, or other:

      * Anxiety (particularly, separation anxiety)
      * Emotional lability (extreme mood swings) and/or depression
      * Irritability, aggression and/or severely oppositional behaviors
      * Behavioral (developmental) regression (examples, talking baby talk,throwing temper tantrums, etc.)
      * Deterioration in school performance
      * Sensory or motor abnormalities
      * Somatic signs and symptoms, including sleep disturbances, bed wetting or urinary frequency
3. Signed informed consent of patient's legal representative(s)/guardians(s). If patients are old enough to understand the risks and benefits of the study (as determined by each institution), they should provide written assent/consent.
4. Legal representative(s)/guardians(s) must be capable of understanding and complying with the relevant aspects of the study protocol.

Patients who will additionally meet the following optional inclusion criteria will be identified as patients with Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS):

1. An episodic (relapsing-remitting) course of symptom severity
2. Temporal association between symptoms onset or exacerbation and infections with group A streptococcal infection (GAS, positive throat culture and/or anti-GAS antibody titers)

Exclusion Criteria

1. Onset of current PANS episode more than 12 months prior to first investigational medicinal product (IMP) treatment.
2. a. In patients with relapsing episodes: Onset of initial PANS episode more than 24 months prior to first IMP treatment.

   b. In patients with relapsing episodes: Absence of significant improvement and stabilization between the episodes according to investigator's judgment.
3. Contraindication to receiving intravenous immunoglobulin (IVIG), including:

   1. History of severe hypersensitivity, e.g. anaphylaxis or severe systemic response, to immunoglobulin, blood or plasma derived products, or any component of Panzyga.
   2. Immunoglobulin (Ig) A deficiency with antibodies to IgA (\<7 mg/dL).
   3. Hyperviscosity syndromes or known or suspected hypercoagulable conditions as inferred from clinical history, which can increase risks of thrombosis associated with IVIG administration.
   4. History of arterial or venous thrombotic or thromboembolic events (TEEs) within the last year prior to Baseline. History of acquired or inherited thrombophilia any time prior to Baseline.
   5. Need for live virus vaccine within three months after receiving study drug.
   6. Renal dysfunction (creatinine \>120 µmol/L or 1.36 mg/dL), history of renal dysfunction, or known risk factor for renal dysfunction (chronic renal insufficiency, diabetes mellitus, taking known nephrotoxic medication). For Italy, estimated glomerular filtration rate (eGFR) needs to be calculated with the 2009 Schwartz equation (eGFR = k \* height/Serum creatinine (Scr), where k is 0.413) \[2\]. eGFR must not be below 30.
4. Severely restricted food intake likely to require parenteral nutrition, and \<5th percentile BMI-for-age (BMI Percentile Calculator for Child and Teen based on Centers for Disease Control and Prevention growth charts for children and teens ages 2 through 19 years)
5. Body mass index ≥ 40 kg/m2
6. Presence of symptoms consistent with autism or schizophrenia, bipolar disorder, or other psychotic disorder (unless psychotic symptoms have onset coincident with PANS).
7. Presence of serious or unstable medical illness, psychiatric (e.g. high suicide risk) or behavioral symptoms that would make participation unsafe or study procedures too difficult to tolerate.
8. Treatment with systemic corticosteroids within eight weeks before randomization.
9. Treatment with NSAIDs within five days before randomization.
10. Treatment with melatonin within one week before randomization
11. History of rheumatic fever, including SC (neurological manifestation).
12. Past treatment of neuropsychiatric symptoms with immunomodulatory therapy (such as IVIG, rituximab or mycophenolate mofetil) or plasmapheresis.
13. Initiation of cognitive behavioral therapy (CBT) within eight weeks before randomization.
14. Start of treatment or change in dosing with selective serotonin reuptake inhibitors \[SSRIs\] within eight weeks before randomization.
15. Treatment with alpha-2 agonists or antipsychotics within eight weeks before randomization.
16. Start of treatment or change in dosing with stimulants (Methylphenidate, Amphetamine and similar products) for Attention-Deficit Hyperactivity Disorder (ADHD) within four weeks prior to randomization.
17. Active use of tetrahydrocannabinol (THC) containing agents within four weeks prior to enrollment or during the trial. Use of cannabidiol- (CBD) / cannabimovone- (CBM) containing agents without THC is allowed if started more than eight weeks before enrollment in a stable dose/frequency.
18. Use of antibiotics or antiviral drugs at therapeutic dose within one week before randomization. Use of antibiotics at a prophylactic dose is allowed if started at least four weeks before randomization (Section 4.2).
19. Severe liver disease (alanine aminotransferase \[ALT\] three times above normal value).
20. Known hepatitis B, hepatitis C or HIV infection as per patient medical history.
21. Cardiac insufficiency (New York Heart Association \[NYHA\] classification III-IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment.
22. Medical conditions with symptoms and effects that could alter protein catabolism and/or IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome).
23. Pregnant and/or lactating women.
24. Female patients of childbearing potential unwilling to use a protocol-required method of contraception (as per protocol Section 7.3.9 b) from Screening throughout the study treatment period and for four weeks following the last dose of study drug. A woman of childbearing potential is defined as a fertile woman or adolescent, from the beginning of menstruation, unless permanently sterile.
25. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within three months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.

Primary outcomes:
measure: CY-BOCS score - Primary
timeFrame: 9 weeks
Secondary outcomes:
measure: CY-BOCS score - Secondary
timeFrame: 18 weeks
measure: Clinical Global Impression
timeFrame: 18 weeks
measure: Parent OC Impact Scale
timeFrame: 18 weeks
measure: Child OC Impact Scale
timeFrame: 18 weeks
measure: SNAP-IV 26 item Scale
timeFrame: 18 weeks
measure: Parent Tic Questionnaire (PTQ)
timeFrame: 18 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Octapharma Research Site
state: Arizona
city: Little Rock
country: United States
facility: Octapharma Research Site
state: Arkansas
city: Los Angeles
country: United States
facility: Octapharma Research Site
state: California
city: Palo Alto
country: United States
facility: Octapharma Research Site
state: California
city: Centennial
country: United States
facility: Octapharma Research Site
state: Colorado
city: Boston
country: United States
facility: Octapharma Research Site
state: Massachusetts
city: Lebanon
country: United States
facility: Octapharma Research Site
state: New Hampshire
city: Genova
country: Italy
facility: Octapharma Research Site
city: Roma
country: Italy
facility: Octapharma Research Site
city: Roma
country: Italy
facility: Octapharma Research Site
city: Goteborg
country: Sweden
facility: Octapharma Research Site
city: Stockholm
country: Sweden
facility: Octapharma Research Site
Study officials:
References: